Paper describes Affiris' PCSK9 vaccine's efficacy

In a paper published in the European Heart Journal, researchers at Affiris AG (Vienna, Austria) showed a vaccine against PCSK9 reduced cholesterol levels and atherosclerosis in mice.

The vaccine, AT04A, consisted of a peptide mimic of a portion of the PCSK9 protein conjugated to an immunogenic carrier. In a mouse model of atherosclerosis, AT04A lowered total cholesterol by 53%, decreased atherosclerotic lesions and plaques, and decreased vascular inflammation 18 weeks after immunization compared with no vaccine. AT04A also elicited antibodies against PCSK9 and decreased PCSK9 plasma concentrations...